Sagimet Biosciences (SGMT) CFO awarded 88,000 options and 44,000 RSUs

Rhea-AI Filing Summary

Sagimet Biosciences Inc. reported that its Chief Financial Officer, Thierry Chauche, received new equity awards. He was granted a stock option for 88,000 shares at an exercise price of $0.0000 per share, which will vest in forty-eight equal monthly installments following February 19, 2026, subject to continued service.

Chauche also acquired 44,000 shares of Series A Common Stock in the form of restricted stock units. Each RSU represents one share and will vest in four equal annual installments following February 19, 2026, contingent on his continued service on each vesting date. After this award, his directly held Series A Common Stock totaled 59,688 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Chauche Thierry

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	88,000	$0.00	--
Grant/Award	Series A Common Stock	44,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 88,000 shares (Direct); Series A Common Stock — 59,688 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chauche Thierry

(Last) (First) (Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO CA 94402

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Series A Common Stock	02/19/2026		A		44,000(1)	A	$0.00	59,688	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.38	02/19/2026		A		88,000		(2)	02/18/2036	Series A Common Stock	88,000	$0.00	88,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

2. The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Elizabeth Rozek, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Sagimet Biosciences (SGMT) disclose in this Form 4 filing?

Sagimet Biosciences reported equity awards to its CFO, Thierry Chauche. He received 88,000 stock options and 44,000 restricted stock units, both granted on February 19, 2026, with multi-year vesting tied to his continued service with the company.

How many stock options did the Sagimet (SGMT) CFO receive and on what terms?

The Sagimet CFO received stock options for 88,000 shares at an exercise price of $0.0000 per share. These options vest in forty-eight equal monthly installments after February 19, 2026, assuming he continues to serve the company through each monthly vesting date.

What are the details of the restricted stock units granted to the Sagimet (SGMT) CFO?

Thierry Chauche was granted 44,000 restricted stock units, each representing one share of Series A Common Stock. The RSUs vest in four equal annual installments following February 19, 2026, provided he remains in service on each applicable vesting anniversary.

How many Sagimet (SGMT) shares does the CFO own after these equity awards?

Following the February 19, 2026 grants, the CFO directly holds 59,688 shares of Sagimet’s Series A Common Stock. This figure reflects his non-derivative holdings after the restricted stock unit award reported in the Form 4 filing.

Are the Sagimet (SGMT) CFO’s new equity awards immediately vested or time-based?

The Sagimet CFO’s equity awards are time-based. The 88,000 stock options vest monthly over forty-eight months, while the 44,000 restricted stock units vest annually over four years, all starting after February 19, 2026, contingent on continued service.